Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib Dose Optimization in Follicular Lymphoma
NCT02536300Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Jan 2016
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of idelalisib in follicular lymphoma (FL), sponsored by Gilead Sciences. Started Jan 2016; status: terminated.
02
Drugs
idelalisib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02536300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02536300.